Phase 2 Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older.
• People who have a confirmed diagnosis (from a tissue sample) of a brain tumour that has come back or stopped responding to treatment — specifically glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), or anaplastic oligoastrocytoma (AOA).
• People whose tumour tissue has been tested and shown to have high levels of a protein called EGFR.
• People who have at least one tumour site that has been confirmed by biopsy and can be measured during the trial.
• People who are reasonably functional in daily life, as measured by a standard health scoring tool (Karnofsky score of 60% or above), and who are expected to survive for at least three months.
• People who have not had chemotherapy in the two weeks before starting the trial treatment, and have not had external beam radiation in the eight weeks before starting.
• People whose blood test results show healthy enough levels of white blood cells, neutrophils (infection-fighting cells), and platelets — with slightly higher platelet levels required for those taking the blood thinner Coumadin.
• People whose liver and kidney function blood tests fall within acceptable ranges set by the trial.
• People whose blood clotting test results are within acceptable ranges set by the trial.
• People who agree to use an effective method of contraception during the treatment period and for three months afterward. Women of childbearing age will be asked to take a pregnancy test before entering the trial.
• People who are able to understand the trial and provide written consent before enrolment.

Who may not be able to join:

• Women who are pregnant or breastfeeding.
• People who have significant ongoing medical or mental health conditions that could put them at greater risk or make it difficult to complete the treatment or follow-up monitoring.
• People whose scans show that the disease has spread to the lining of the brain or spinal cord (leptomeningeal disease).
• People who have previously had an allergic reaction to CTX (the treatment used in this trial).
• People who finished a combined chemotherapy and radiation treatment program less than six months before enrolling.
• People who have not yet tried and been found to have an inadequate response to the standard first-line treatment for this type of brain tumour (known as the Stupp protocol) (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.